Follistatin Restores Perivascular Adipose Function in Hypertensive Vessels
Essential hypertension does not damage arteries through pressure alone. It also reshapes the tissue that surrounds them, and that surrounding tissue can stop behaving like a brake on vasoconstriction and start acting like an accomplice. In this study, follistatin improved vascular dysfunction in spontaneously hypertensive rats by acting directly on perivascular adipose tissue rather than simply lowering blood pressure.
The work centers on a biological problem that has gained increasing attention in vascular medicine: PVAT is normally anti-contractile, but in hypertension it becomes dysfunctional, more oxidative, and more contractile. Once reactive oxygen species rise, nitric oxide signaling weakens, vascular tone shifts toward constriction, and the vessel wall loses one of its local protective mechanisms. The findings here place follistatin squarely in that pathway, linking its benefit to oxidative stress reduction, activin neutralization, and AMP-activated protein kinase signaling.
Oxidative Stress, Browning, and the Loss of PVAT Protection
The study used spontaneously hypertensive rats treated for eight weeks with vehicle, follistatin, or hydralazine. Mesenteric white PVAT and thoracic brown PVAT from hypertensive and normotensive animals were examined, and vascular responses were assessed with wire myography. PVAT nitric oxide, reactive oxygen species, and browning markers were then evaluated, with additional ex vivo work and unbiased proteomic analysis used to map the mechanism.
A single conclusion runs through the dataset: hypertensive PVAT had become procontractile, and follistatin reversed that phenotype. The reversal was not cosmetic. It tracked with lower ROS, greater nitric oxide bioavailability, and a shift toward browning, a metabolic state associated with more favorable vascular signaling. In other words, the adipose tissue surrounding the vessel regained some of the characteristics that normally help relax the underlying smooth muscle.
Brown adipose-like programming matters because it is tied to higher mitochondrial activity and improved handling of oxidative burden. In the context of PVAT, that metabolic shift appears to preserve local vasodilatory tone. The study’s proteomic findings aligned with that interpretation, showing a move toward a more normal protein expression profile and an upregulation of pathways associated with adipose browning.
Hydralazine Lowered Pressure Without Recreating the Tissue Effect
The contrast with hydralazine was striking. Although hydralazine reduced blood pressure, it did not reproduce the vascular benefits seen with follistatin. That separation matters because it argues against a simple hemodynamic explanation. If pressure lowering alone were sufficient, the drug that reduced systemic pressure would be expected to correct the PVAT abnormality as well. It did not.
This divergence points to a direct tissue effect. Follistatin neutralized activin and increased AMPK phosphorylation, two signals that appear to drive the adipose remodeling. By lowering oxidative stress and restoring nitric oxide availability, the treatment changed the local vascular environment in a way that hydralazine did not. The vessel wall benefited not just from less pressure, but from a healthier adipose interface wrapped around it.
A Direct Mechanistic Link From Activin Neutralization to Browning
The mechanistic work makes the study more than a phenotype report. Ex vivo PVAT experiments showed that the browning response depended on activin neutralization and AMPK activation. Those pathways fit together plausibly. Activin antagonism can alter adipose lineage signaling, while AMPK is a known metabolic sensor that promotes energy-utilizing, browning-associated programs. In hypertensive PVAT, where oxidative stress is high and vasorelaxant support is impaired, that combination offers a biologically coherent route to recovery.
The study also connects nitric oxide and reactive oxygen species in a way that has direct vascular relevance. Excess reactive oxygen species consume nitric oxide and blunt its relaxing effect on vascular smooth muscle. When follistatin reduced oxidative stress, nitric oxide bioavailability rose, and the anti-contractile role of PVAT re-emerged. That is the kind of local correction that can influence vascular tone even before any systemic effect becomes visible.
Why the Findings Matter for Vascular Dysfunction in Hypertension
Essential hypertension remains a leading modifiable cause of death worldwide, and much of its burden comes from the cumulative damage to vascular structure and function. PVAT is an attractive target because it sits immediately beside the vessel wall and signals in real time to the underlying artery. A therapy that can reprogram that tissue could, in principle, improve vascular function without relying only on broad systemic vasodilation.
The data here support that possibility in a preclinical model. Follistatin restored PVAT-mediated vascular relaxation through a chain of events that included oxidative stress reduction, activin neutralization, AMPK-dependent browning, and recovery of nitric oxide signaling. The observed proteomic shift toward a more normal state strengthens the case that the tissue was not merely less inflamed or less stressed, but biologically reprogrammed.
For clinicians and translational researchers, the central message is practical: vascular dysfunction in hypertension may be partly sustained by dysfunctional surrounding fat, and that tissue can be pharmacologically modified. The study does not establish human efficacy, and it does not replace the need for blood pressure control. It does, however, identify PVAT as a mechanistically rich target that could complement standard antihypertensive therapy if the findings translate beyond the rat model.
What the Rat Model Can and Cannot Prove
The work remains preclinical, and the model is limited to spontaneously hypertensive rats with mesenteric and thoracic tissue sampling. Human PVAT biology may not mirror these findings exactly, and no clinical outcomes were measured. The study also does not answer whether chronic follistatin exposure would be safe or durable in people, or whether the same effect would appear across different vascular beds.
Even with those limits, the mechanistic signal is unusually coherent. The treatment effect was tied to a specific tissue compartment, a specific oxidative pathway, and a specific metabolic shift rather than to blood pressure reduction alone. That leaves a concrete translational question: can PVAT browning and oxidative stress control be harnessed to improve vascular function in essential hypertension without relying solely on conventional hemodynamic lowering?